NEW YORK, Aug. 17 (GenomeWeb News) - Odyssey Thera will license its protein-fragment complementation assays to the National Institutes of Health to aid in the federal body's Molecular Libraries Roadmap Initiative, Odyssey said today.
The NIH will use the assays for screening small molecules with relevance to pharmaceutical discovery. According to the NIH, research using the technology will be conducted at the NIH's
Financial details were not disclosed.